D Pharm is due to announce receipt of the Phae III trial's interim results by March 2012.
D-Pharm Ltd. (TASE: DPRM) today reported that the Data and Safety Monitoring Board recommends the company's ischemic stroke treatment DP-b99, after it proved safe in a Phase III clinical trial.
The Data and Safety Monitoring Board is an independent body of neurologists and biostatisticians set up on the basis of US Food and Drug Administration (FDA) protocols. The board met after the monitoring period for all the patients in the clinical trial was completed.
D Pharm is due to announce receipt of the clinical trial's interim results by March 2012.
D Pharm's share price fell 2% today to NIS 11.05, giving a market cap of NIS 164 million.
Published by Globes [online], Israel business news - www.globes-online.com - on July 20, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011